Serum concentrations of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3), the carboxyterminal propeptide oftype I collagen (PICP), the carboxyterminal pyridinoline crosslinked telopeptide of type I collagen (ICTP), and the aminoterminal propeptide of type III procoliagen (PIIINP) were studied in 10 prepubertal children with asthma (mean age 9-0 years). The children were treated with 2*5 and 5*0 mg/day prednisolone in a randomised double blind crossover trial with run in, treatment, and washout periods of two weeks.
attempts to elucidate the mechanisms of glucocorticosteroid induced growth suppresion.
Growth, however, requires synthesis of collagen. Type I collagen is the most abundant collagen type in connective tissues and accounts for more than 90%/ of the organic matrix of bone. 12 Type III collagen is present in dense and loose connective tissues throughout the body. 13 The serum marker of type I collagen synthesis, the carboxyterminal propeptide of type I collagen (PICP), is decreased during glucocorticosteroid treatment in adults'4 15 and in children. [16] [17] [18] In adults glucocorticosteroids have also been found to reduce serum concentrations of the marker of degradation of type I collagen, serum carboxyterminal pyridinoline crosslinked telopeptide of type I collagen (ICTP)15 19 and of the marker of type III collagen synthesis, the aminoterminal propeptide of type III procollagen (PIIINP) . 14 At present there are no evaluations of dose related effects of exogeneous glucocorticosteroids on any of these parameters in children. The aim of this study was to evaluate whether prednisolone by mouth in doses of 2-5 and 5 mg/day has any adverse effects on serum concentrations of IGF-I, IGFBP-3, and the markers of collagen turnover PICP, ICTP, and PIIINP in children.
Patients and methods
The protocol was part of a clinical study of IGF-I, IGFBP-3, and markers of collagen metabolism were assessed at day 14 in period 1 (run in) and periods 2 and 4 (treatment periods). Blood samples were taken at roughly the same time (that is, within one hour) in the afternoon (between 3 and 6 pm). The samples were centrifuged at 3000 rpm for 10 minutes within one hour after they were taken. Serum was frozen and stored at -20°C and batch assayed at the completion of the study. IGF-I was analysed by a specific radioimmunoassay as previously described,20 with some modifications. The interassay and intra-assay variations were 10O0% and 10 0% for PICP determinations (at B/BO 0 33) and 8-0% and 7-2% respectively for PIIINP (at B/BO 0 43).
The serum carboxyterminal pyridinoline crosslinked telopeptide of type I collagen was determined by specific radioimmunoassay (ICTP-RIA-kit, Orion Diagnostica, Finland) as described by Risteli et (0 7) ,ug/l). STATISTICAL 
ANALYSIS
To be able to compare IGF-I, IGFBP-3, PICP, and PIIINP with normal reference values, SD scores were calculated by the following equation: (observed value-mean)/l SD. Age and sex related means and SDs from normal children were used (unpublished data).21 24 As good normative data were not available for comparisons of the ICTP data they are presented as raw data.
The data for each parameter during run in and treatment periods were compared by the method described for crossover trial designs.25 Neither a period nor carryover effect was found. Page's test for trend was used to evaluate if there was any dose related effects of the treatments.26 The 5% level was considered significant.
Results
There were five children in each blinded dose sequence group.
The run in SD scores (SEM) for IGF-I, IGFBP-3, PICP, and PIIINP were -0-6 (0 2), +0 7 (0 3), -0-1 (0 2), and -0-5 (0-2) respectively. None of these parameters differed significantly from zero. The ICTP concentrations were 6-6 -12-2 ,lg/l (mean (SEM) 9-7 (05)) -that is, within the range determined in healthy children. -9 (16-9) ,uLg/l respectively (p=0 37; z=0 9). The concentration of IGFBP-3 was increased with 203-4 (144-0) and 31.85 (195-6) ,ugfl during the two dose levels (p= 0l12; z= 1-6). and 2-9 (0 6) pug/l (p<0 001; z=-3 9) and PIIINP with 2<1 (0 7) and 3d1 (1-8) ,ug/l (p<0 001; z=-4 0)) during the 2-5 and 5-0 mg prednisolone periods respectively. Concentrations of PICP are decreased in inflammatory diseases such as rheumatoid arthritis, whereas ICTP may be increased. '5 The run in values of PICP, ICTP, and PIIINP in this group of children with mild asthma with normal pulmonary function did not differ significantly from the values in normal children. Therefore, it seems unlikely that the suppressive effect of prednisolone on the markers of collagen turnover could reflect any anti-inflammatory effect of the drug. Furthermore, animal studies have shown that exogeneous glucocorticosteroids do not affect the hepatic clearance rate of procollagen propeptides (unpublished data). Finally, glucocorticosteroids have long been known to suppress the synthesis of interstitial procollagens in vitro and in normal adults.30 31 The observed reductions in serum concentration of PICP, ICTP, and PIIINP must therefore reflect the catabolic effect of prednisolone. 1858-63). Up to July 1992 some 645 000 babies were screened. One hundred tests were positive but on further investigation only 50 babies were shown to have congenital infection. All of these 50 were normal on routine neonatal examination but nine had retinal lesions on ophthalmological assessment.
Five babies with severe toxoplasma brain disease were identified independently of the screening programme. Only two of these had a positive IgM antibody screening test.
Forty six children completed a 12 month course of treatment with pyrimethamine, leucovorin, and either sulphadiazine or spiramycin. Thirteen had anaemia, neutropenia, or both during treatment, one developed a rash, and one was inadvertently given an excessive dose of pyrimethamine. Four children apparently developed new retinal lesions on or following treatment. As there was no untreated group the effectiveness of the treatment is not known. It is suggested that these children did well in comparison with those in previous follow up studies of untreated children.
The screening test, therefore, was negative in 60% of children with grossly symptomatic congenital infection and 50% of positive tests were apparently false positives. Treatment is not devoid of problems and whether it is effective is uncertain. There seems to be a lot more work to be done before the authors' (muted) enthusiasm is likely to be shared by many. 
